CN100418559C - Chinese medicinal composition for treating postartum and abortive complication and its preparing method - Google Patents
Chinese medicinal composition for treating postartum and abortive complication and its preparing method Download PDFInfo
- Publication number
- CN100418559C CN100418559C CNB2003101022832A CN200310102283A CN100418559C CN 100418559 C CN100418559 C CN 100418559C CN B2003101022832 A CNB2003101022832 A CN B2003101022832A CN 200310102283 A CN200310102283 A CN 200310102283A CN 100418559 C CN100418559 C CN 100418559C
- Authority
- CN
- China
- Prior art keywords
- weight portion
- herba
- chinese medicine
- medicine composition
- herba leonuri
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 98
- 239000003814 drug Substances 0.000 claims abstract description 76
- 239000002775 capsule Substances 0.000 claims abstract description 66
- 206010000210 abortion Diseases 0.000 claims abstract description 34
- 231100000176 abortion Toxicity 0.000 claims abstract description 33
- 238000002360 preparation method Methods 0.000 claims abstract description 20
- 239000008187 granular material Substances 0.000 claims abstract description 10
- 239000007924 injection Substances 0.000 claims abstract description 10
- 238000002347 injection Methods 0.000 claims abstract description 10
- 208000035965 Postoperative Complications Diseases 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
- 239000002994 raw material Substances 0.000 claims abstract 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 26
- 239000000706 filtrate Substances 0.000 claims description 24
- 239000000341 volatile oil Substances 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 16
- 229920000858 Cyclodextrin Polymers 0.000 claims description 13
- 239000001116 FEMA 4028 Substances 0.000 claims description 13
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 13
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 13
- 229960004853 betadex Drugs 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 238000010992 reflux Methods 0.000 claims description 12
- 238000004321 preservation Methods 0.000 claims description 8
- 206010058046 Post procedural complication Diseases 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 238000001256 steam distillation Methods 0.000 claims description 6
- 238000003825 pressing Methods 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 244000286838 Eclipta prostrata Species 0.000 claims 3
- 241000219295 Portulaca Species 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 240000002853 Nelumbo nucifera Species 0.000 claims 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 28
- 239000008280 blood Substances 0.000 abstract description 15
- 210000004369 blood Anatomy 0.000 abstract description 15
- 208000002193 Pain Diseases 0.000 abstract description 7
- 230000036407 pain Effects 0.000 abstract description 7
- 206010046910 Vaginal haemorrhage Diseases 0.000 abstract description 6
- 230000033228 biological regulation Effects 0.000 abstract description 4
- 235000008216 herbs Nutrition 0.000 abstract 3
- 230000032696 parturition Effects 0.000 abstract 2
- PBQVHWFDMNCCIH-KNJAVFAGSA-N (4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;n,n-dimethyl-1-phenothiazin-10-ylpropan-2-amine;n-(4-hydroxyphenyl)acetamide;phosphoric acid;hydrochloride Chemical compound Cl.OP(O)(O)=O.CC(=O)NC1=CC=C(O)C=C1.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1.C([C@H]1C(N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC PBQVHWFDMNCCIH-KNJAVFAGSA-N 0.000 abstract 1
- 208000004998 Abdominal Pain Diseases 0.000 abstract 1
- 241000758794 Asarum Species 0.000 abstract 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 abstract 1
- 244000150195 Cyperus longus Species 0.000 abstract 1
- 235000018109 Cyperus longus Nutrition 0.000 abstract 1
- 244000075634 Cyperus rotundus Species 0.000 abstract 1
- 235000013717 Houttuynia Nutrition 0.000 abstract 1
- 240000000691 Houttuynia cordata Species 0.000 abstract 1
- 240000007890 Leonurus cardiaca Species 0.000 abstract 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 abstract 1
- 244000234609 Portulaca oleracea Species 0.000 abstract 1
- 235000001855 Portulaca oleracea Nutrition 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 235000005010 Scirpus paludosus Nutrition 0.000 abstract 1
- 206010046788 Uterine haemorrhage Diseases 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 238000004821 distillation Methods 0.000 abstract 1
- 239000006196 drop Substances 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000008176 lyophilized powder Substances 0.000 abstract 1
- 239000006187 pill Substances 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 28
- 210000004291 uterus Anatomy 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000012360 testing method Methods 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 230000037396 body weight Effects 0.000 description 12
- 210000002460 smooth muscle Anatomy 0.000 description 12
- 238000010998 test method Methods 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 230000035935 pregnancy Effects 0.000 description 10
- 240000001624 Espostoa lanata Species 0.000 description 9
- 235000009161 Espostoa lanata Nutrition 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 206010000234 Abortion spontaneous Diseases 0.000 description 7
- 206010053567 Coagulopathies Diseases 0.000 description 7
- 230000035602 clotting Effects 0.000 description 7
- 208000015994 miscarriage Diseases 0.000 description 7
- 230000002980 postoperative effect Effects 0.000 description 7
- 208000000995 spontaneous abortion Diseases 0.000 description 7
- 206010018691 Granuloma Diseases 0.000 description 6
- 206010027514 Metrorrhagia Diseases 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 206010000087 Abdominal pain upper Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 5
- 101800000989 Oxytocin Proteins 0.000 description 5
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 5
- 229960001723 oxytocin Drugs 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012109 statistical procedure Methods 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000003433 contraceptive agent Substances 0.000 description 3
- 230000002254 contraceptive effect Effects 0.000 description 3
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 3
- 229960000452 diethylstilbestrol Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960003248 mifepristone Drugs 0.000 description 3
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000013948 uterine smooth muscle contraction Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000040350 B family Human genes 0.000 description 2
- 108091072128 B family Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 2
- 229960005249 misoprostol Drugs 0.000 description 2
- 238000011206 morphological examination Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010223 real-time analysis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000246 remedial effect Effects 0.000 description 2
- 230000016160 smooth muscle contraction Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000006216 vaginal suppository Substances 0.000 description 2
- 229940120293 vaginal suppository Drugs 0.000 description 2
- 241001671653 Aconitum carmichaelii Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZXKXJHAOUFHNAS-UHFFFAOYSA-N fenfluramine hydrochloride Chemical compound [Cl-].CC[NH2+]C(C)CC1=CC=CC(C(F)(F)F)=C1 ZXKXJHAOUFHNAS-UHFFFAOYSA-N 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000008246 gaseous mixture Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- ZSPLOATUDIRNAS-PPHPATTJSA-N levofloxacin mesylate Chemical compound CS(O)(=O)=O.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 ZSPLOATUDIRNAS-PPHPATTJSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 230000003191 uterotonic effect Effects 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a Chinese medicinal composition for treating and preventing postoperative complications after parturition and artificial abortion and a preparation method of the Chinese medicinal composition. The composition is mainly prepared from motherwort, chuanxiong rhizomes, heartleaf houttuynia herbs, nutgrass galingale rhizomes, ecliptae herbs, purslane herbs, etc. During preparing the Chinese medicine composition, methods of distillation, decoction and alcohol deposition are respectively used for different raw material medicines, so that effective components are sufficiently dissolved, and a excipient which is acceptable on pharmacology is directly or indirectly added for preparing preparations which is acceptable in a clinic through a scientific working procedure. The Chinese medicinal composition comprises the preparations of tablets, oral liquid, capsules, drop pills, granules, injections, lyophilized powder, various sustained-release formulations, etc. The composition has the favorable efficiency of blood stasis removal, evil elimination, qi regulation, pain stop, yin enrichment and blood nourishment and has the good functions for treating and preventing vaginal bleeding, waist pain, abdominal pain and fever which occur after parturition and the operation of artificial abortion.
Description
Invention field
The present invention relates to a kind of Chinese medicine composition, particularly be used for the treatment of, prevent puerperal and postoperative complication of artificial abortion's Chinese medicine composition, relate to the preparation method of said composition simultaneously.
Background technology
Family planning work belongs to China's fundamental state policy scope.Be faced with the new situations of population and social development, entering present stage still is this characteristics.And seem more outstanding and distinct.As the people constitution of health, people's quality is united mutually with the progress of country preferably.
Over year, obtained significant effect surplus China's family planning work nearly 30.The rate of contraception has surpassed world standard, even so, but also should see and and sum up and is prevented the deficiency relevant with family planning and the aspect of shortage, give possible measure, this is the needs of national policy, also is the needs of scientific progress, especially the needs in the drug flow.
Artificial abortion is not contraceptive device, but is indispensable part in the planning of family planning, does not have the remedial measure of artificial abortion, faces the reality, must the women of contraceptive failure takes artificial abortion to solve their demand to being reluctant to give birth to.Artificial abortion has simultaneously become the important measures that various countries control birth rate then, and China is so equally.
All gestation 3 months with interior with artificial abortion or pharmaceutical methods termination of pregnancy, be referred to as artificial abortion.It is the remedial measure of contraceptive failure.
In recent years, the artificial abortion number is increasing year by year both at home and abroad.According to China's Ministry of Public Health statistics in 1996.China has 1,300 ten thousand person-times every year approximately, and the young woman of fertility does not require the artificial abortion number, accounts for the 22.9%-42.7% (at present may be more outstanding) of artificial abortion sum according to statistics.
The present invention also once to the first visit patient of two departments, to suffering from gynaecopathia, wherein has history of artificial abortion person to do actual survey before exploitation.As: in 1035 first visits of A ground, artificial Aborter 383 people were arranged, its ratio is 37%; B ground 480 first visit patients have history of artificial abortion person 167 people, its ratio 34.79%.Two groups add up to 1515 people, and it is 550 people that artificial abortion person is arranged, and its ratio is 36.30%.Also once to the patient about 17 people is arranged in 50 person-times of outpatient service numbers every day, history of artificial abortion is arranged, its ratio is about 34%.
This has history of artificial abortion person's details tabulation reference for once 1035 examples being suffered from gynaecopathia:
| Name of disease | Infertile | Amenorrhea | Polycystic ovary | Infrequent menstruation | The inner membrance dystopy | The back is wrong | Rare | Anovulatory dysfunctional uterine hemorrhage | Pelvic inflammatory disease | Other |
| Number | 376 | 102 | 145 | 59 | 59 | 22 | 14 | 46 | 158 | 58 |
| Artificial abortion's history | 102 | 36 | 54 | 24 | 29 | 15 | 9 | 14 | 84 | 16 |
Though sample is little, also can find out some phenomenons, the artificial abortion postoperative is owing to multiple factor, and the long term complication that causes is a kind of relatively medical science and social problem of significant.
Artificial abortion should belong to householder method in family planning advice, very much progress is all arranged aspect technical operation both at home and abroad.For the processing of early stage postoperative, be very much perfect.But in recent years, by problem that most scholar paid attention to.Recent and the difference of long term complication and the part that links have wherein been seen.From the relevant report in the world, see having every year 2000 ten thousand women to suffer the harm of unsafe artificial abortion (artificial abortion of non-full finger negative pressure) approximately, and have millions upon millions of above women tormented by prolonged sickness, even disability.As seen, the timely maintenance measure of artificial abortion postoperative should be to be very much important link.
The artificial abortion postoperative all gives preventive drug though be expert at present, and disunity.As single antibiotic medicine of use, or singly with blood stasis dispelling medicines such as YIMUCAO CHONGJI, with the traditional Chinese medical science to women's health post-abortion on the occasion of state on the decline, except that self disorder of QI and blood, also be the comparison weakness for the power of resisting ruthless and tyrannical pathogen.So cause morbidity easily.As the poly-pelvic cavity of noxious dampness knot, or pathogenesis such as blood stasis retrograde stationary pelvic cavity, all be to have disease visible.How to enter this prevention and control field, Gynecology of Chinese Medicine has its foundation, and the health that should be numerous women considers, and also should be explored.
Summary of the invention
One object of the present invention is to disclose a kind of new treatment, prevention puerperal and postoperative complication of artificial abortion's Chinese medicine composition; Another object of the present invention is a kind of new treatment of open preparation, the preparation method of preventing puerperal and postoperative complication of artificial abortion's Chinese medicine composition.
The crude drug of pharmaceutical composition of the present invention is formed and proportioning following (by weight):
A scheme: Herba Leonuri 5-20 weight portion Rhizoma Chuanxiong 1-10 weight portion Herba Ecliptae 5-20 weight portion.
A scheme crude drug proportion optimization following (by weight):
Herba Leonuri 7-15 weight portion Rhizoma Chuanxiong 1-6 weight portion Herba Ecliptae 7-15 weight portion.
The crude drug of pharmaceutical composition of the present invention is formed and proportioning can also be (by weight):
B scheme: Herba Leonuri 5-20 weight portion Rhizoma Chuanxiong 1-10 weight portion Herba Houttuyniae 5-20 weight portion Herba Ecliptae 5-20 weight portion Herba Portulacae 5-20 weight portion.
B scheme crude drug proportion optimization following (by weight):
Herba Leonuri 7-1 5 weight portion Rhizoma Chuanxiong 1-6 weight portion Herba Houttuyniae 7-15 weight portions
Herba Ecliptae 7-15 weight portion Herba Portulacae 7-15 weight portion.
The crude drug of pharmaceutical composition of the present invention is formed and proportioning can also be (by weight):
C scheme: Herba Leonuri 5-20 weight portion Rhizoma Chuanxiong 1-10 weight portion Herba Houttuyniae 5-20 weight portion Rhizoma Cyperi 3-12 weight portion Herba Ecliptae 5-20 weight portion Herba Portulacae 5-20 weight portion.
C scheme crude drug proportion optimization following (by weight):
Herba Leonuri 7-15 weight portion Rhizoma Chuanxiong 1-6 weight portion Herba Houttuyniae 7-15 weight portion
Rhizoma Cyperi 5-9 weight portion Herba Ecliptae 7-15 weight portion Herba Portulacae 7-15 weight portion.
The preferred Rhizoma Cyperi (processed) of above-mentioned Rhizoma Cyperi.
The preparation method of C scheme Chinese medicine composition of the present invention is:
Above Six-element, Rhizoma Cyperi (processed) add water 4-10 doubly to be measured, and steam distillation 3-10 hour, extract volatile oil, aqueous solution is continued to employ; Add water 5-15 after medicinal residues and Herba Leonuri, Herba Portulacae, Herba Ecliptae and Herba Houttuyniae mix and doubly measure, decoct 1-5 time, each 1-5 hour, filter; Merging filtrate and the above-mentioned aqueous solution of carrying behind the oil, being concentrated into relative density is 1.10-1.20 (45-60 ℃ of survey), adds ethanol and makes determining alcohol reach 30-90%, placement is spent the night, and filters.Volatile oil cold preservation 20-28 hour, filters cold drying with betacyclodextrin inclusion (volatile oil-betacyclodextrin-water=1-3: 6-10: 80-120,50-70 ℃ was stirred 1-4 hour).Rhizoma Chuanxiong adds 3-10 and doubly measures the 50-90% alcohol reflux 1-3 time, each 1-3 hour, filter, filtrate and above-mentioned alcohol deposit fluid merge, reclaim ethanol and be concentrated into the thick paste that relative density is 1.28-1.30 (45-60 ℃ of survey), drying under reduced pressure, be ground into fine powder, mix with volatile oil betacyclodextrin inclusion complex, directly or indirectly add pharmaceutically acceptable excipient through conventional operation and make clinical acceptable forms, as tablet, oral liquid, capsule, granule, injection, freeze-dried powder and various slow releasing preparation etc.
A of the present invention, B, C scheme composite preparation have that good blood stasis dispelling is eliminating evil, regulating QI to relieve pain, tonifying YIN nourish blood effect, and vaginal hemorrhage, waist stomachache, heating that puerperal and artificial abortion postoperative are occurred have good treatment, preventive effect; The disclosed present composition preparation of pharmacological evaluation has that fine inhibition uterine smooth muscle thickens, hemostasis, antiinflammatory, analgesia, pharmacological action such as antibacterial, and this also fully shows the good action of present composition preparation aspect treatment, prevention puerperal and postoperative complication of artificial abortion; The safety of present composition preparation clinical practice simultaneously has no side effect.
Following experimental example further specifies the present invention.
Below the used Herba Leonuri peace of experiment palace capsule is a C scheme composition capsule preparation of the present invention.
Experimental example 1 pharmacological evaluation
Test material: be subjected to the reagent thing: Herba Leonuri peace palace capsule, contain the dried cream of 20.25g crude drug/g, face with preceding and prepare to desired concn with distilled water.The dosage design: clinical consumption is 48g crude drug/d, presses 60kg and calculates, be i.e. 0.8g crude drug/kg/d.Press the conversion of animals and human beings kg body weight dose,equivalent, mice is used 2.5g/kg/d (3.1 times) with 8.8g/kg/d (11 times), rat with 4.4g/kg/d (5.4 times), rabbit, and being equivalent to clinical equivalent dosage is middle dosage, high dose is 2 times of middle dosage, and low dosage is 1/2 times of middle dosage.Positive control drug: Herba Leonuri granule, certain product that goes on the market, lot number: 020612, Coming-of-Age Day consumption 30g/d, 60kg is calculated as 0.5g/kg by average weight, and mice is used 3.1g/kg with 11.0g/kg, rabbit; GONGXUENING JIAONANG, certain product that goes on the market, lot number: 010605, Coming-of-Age Day consumption 0.78g/d, 60kg is calculated as 0.013g/kg by average weight, rat is used 0.286g/kg with 0.14g/kg, mice, more than all be equivalent to 2 times of clinical equivalent dosage.Aspirin, certain product that goes on the market, lot number: 010626, laboratory conventional amount used 0.05g crude drug/kg.Dosage and route of administration: the mice dosage is 20ml/kg; The rat dosage is 10ml/kg, adopts the gastric infusion mode, and the rabbit dosage is 2ml/kg, adopts 12 rectally modes.Animal: mice Kunming kind, body weight 20 ± 2g; Beijing Biological Product Inst. provides, and the quality certification number is betrothed to 1999 No. 012 for the capital is moving; Rat, the SD kind, body weight 200 ± 20g is provided by Beijing Vital River Experimental Animals Technology Co., Ltd., quality certification SCXK (capital)-02-0003; Rabbit is provided by Academy Road,BeiJing tonneau experimental animal plant, the quality certification number the 024th total No. 069.Reagent: diethylstilbestrol, Shanghai the 9th pharmaceutical factory, lot number: 010102; The mifepristone sheet, Zizhu Pharmaceutical Co., Ltd., Beijing produces, lot number: 43020305; The misoprostol sheet, SearlePharmaceuticals Englishi (Britain), lot number: 2070 FEB2004; Oxytocin inj, the Shanghai first biochemical Pharma Inc., biochemical-pharmaceutical factory, Shanghai, lot number: 020161; Formaldehyde, the Beijing Chemical Plant produces, lot number: 840601.(U.S.) pentobarbital sodium, chemical experimental factory, Foshan City, lot number: 860901.Bacteria culture staphylococcus aureus, escherichia coli, bacillus pyocyaneus, B family streptococcus.Identify and provide by Peking University First Hospital Bacteriology Room.Culture medium trypsinization soya peptone agar (TSB) and yeast powder are Britain OXOID product; M-agar is produced by Beijing overpass commodity inspection New Tech S. R. L., lot number: 000317.Material and instrument: disinfection of surgical equipment; ZS-3 type semi-automatic biochemical analyzer is gone up marine living biological engineering High-tech company and is produced; EP type electronic balance, day island proper Tianjin Zhu Shi commercial firm produces; MP-100 leads physiology recording system, the U.S. more; Thermostatic drying chamber, Chaoyang District Beijing are extensively sought medical apparatus and instruments factory.
[test method and result]
1. Herba Leonuri peace palace capsule causes the influence of pregnant Mus miscarriage to medicine
1.1 Herba Leonuri peace palace capsule causes the influence of pregnant rat miscarriage early to medicine
1.1.1 test method mates rat in ratios female, male 2: 1, observe female rats morning next day and have or not vaginal suppository, to find that it is gestation the 1st day that vaginal suppository is arranged.The rat that to become pregnant is divided into 5 groups at random by body weight, be respectively model group, the positive drug group, be subjected to the reagent height, in, low three dosage groups, the normal control group is without any processing, only be used for pathological observation, every group 10, in becoming pregnant the 7th day, all the other each groups are irritated stomach mifepristone 8.3mg/kg (8:00 in the morning) and misoprostol 100ug/kg (4:00 in afternoon) 10ml/kg respectively except that normal group, every Mus is inserted quantitative cotton balls 0.072-0.075g in intravaginal simultaneously, i.e. pregnancy beginning on the 8th next day gastric infusion after the modeling, normal group and model group give isopyknic distilled water, once a day, successive administration 7 days is changed cotton balls every day, with the cotton balls that the takes out airtight stored refrigerated in the plastic bag of packing into, be collected into continuously and become pregnant the 14th day.The 15th day rat tail vein of becoming pregnant got blood 20ul, adds in 4ml (50g/L) sodium hydroxide solution, and mixing is to be measured.Pregnant Mus is put to death, take out the uterus, do the pathology histological examination.The cotton balls that every Mus is collected continuously is with an amount of 50g/L sodium hydroxide solution lixiviate, getting the 5ml lixiviating solution filters, with the 50g/L sodium hydroxide solution is blank, with spectrophotometer under the 545nm wavelength, measure tail vein sodium hydroxide solution A value and uterus lixiviating solution A value, by the metrorrhagia amount in the following formula calculating modeling 7 days: check with t and to carry out statistical procedures.
In the formula: V
2Amount (ml) for the used 50g/L sodium hydroxide of lixiviate uterus blood
V
1Amount (ml) for the used 50g/L sodium hydroxide of dilution venous blood
1.1.2 experimental result by table 1 result as seen, Herba Leonuri peace palace capsule can reduce drug induced abortion and cause the metrorrhagia amount of pregnant rat early.Uterine cancer cell morphological examination result shows (table 2, attached photo and pathological replacement), and Herba Leonuri peace palace capsule obviously suppresses endometrial thickness, has compared significant difference with model control group, and high dose group thickens uterine smooth muscle also certain inhibition effect.
Table 1 Herba Leonuri peace palace capsule is to the influence of early pregnancy miscarriage rat uterus amount of bleeding
Annotate: compare * p＜0.05 with matched group
Table 2 Herba Leonuri peace palace capsule is to the influence of early pregnancy miscarriage rat tissue form
Annotate: compare * p＜0.05, * * p＜0.01 with model control group
1.2 Herba Leonuri peace palace capsule causes the influence of early pregnancy mice miscarriage metrorrhagia amount to medicine
1.2.1 test method mates mice in ratios female, male 2: 1, carry out vaginal smear examination morning next day, serves as gestation the 1st day to find sperm.The mice that to become pregnant is divided into 5 groups at random, is respectively matched group, is subjected to large, medium and small three the dosage groups of reagent, positive drug group, every group 10,, irritate stomach mifepristone 12.5mg/kg with the modeling in the 7th day of becoming pregnant, volume is 10ml/kg, every Mus is inserted quantitative sponge 0.032-0.035g in intravaginal simultaneously, modeling administration on the same day, and model group gives isopyknic distilled water, successive administration 5 days, change sponge every day,, be collected into continuously and become pregnant the 11st day the sponge of the taking out airtight stored refrigerated in the plastic bag of packing into.The metrorrhagia amount of mensuration in modeling 5 days, method and calculate the same.
1.2.2 experimental result by table 3 result as seen, Herba Leonuri peace palace capsule institute amount of reagent can obviously reduce the metrorrhagia amount that drug induced abortion causes the early pregnancy mice.
Table 3 Herba Leonuri peace palace capsule is to the influence of early pregnancy Mouse Uterus amount of bleeding
Annotate: compare * p＜0.05 with matched group
Herba Leonuri peace palace capsule to animal go out, the influence of clotting time
2.1 Herba Leonuri peace palace capsule is to the influence of clotting time of mice
2.1.1 test method is got 50 of body weight 18-22g Healthy female mices, be divided into 5 groups immediately by body weight, every group 10, matched group, the GONGXUENING JIAONANG group, the high, medium and low dosage group of Herba Leonuri peace palace capsule, every day, gastric infusion was 1 time, and matched group gives the distilled water with volume, continuous 7d, behind the last administration 1h, insert Mus angular vein clump, on take a blood sample two and the slide with capillary tube, choose once with syringe needle every 10s, occur the blood clotting silk time from taking a blood sample to, be clotting time, gained data and matched group carry out the t check.
Table 4 Herba Leonuri peace palace capsule is to the influence of clotting time of mice
Annotate: compare * p＜0.05, * * p＜0.01 with matched group
2.1.2 result of the test table 4 result shows that Herba Leonuri peace palace capsule institute amount of reagent all can shorten the clotting time of mice.
2.2 Herba Leonuri peace palace capsule is to the influence in mice bleeding time
[2]
2.2.1 the grouping of test method animal, administration are equal to the clotting time of mice experiment, last administration 0.5h, in order to cutting mouse tail point 0.5cm place is cut off respectively, when blood flows out postscript voluntarily, inhale to dehematize with filter paper every 10s and drip once, stop voluntarily until blood, calculate the bleeding time, gained data and matched group carry out the t check.
2.2.2 result of the test table 5 result shows that Herba Leonuri peace palace capsule institute amount of reagent all can shorten the bleeding time of mice, showing has stronger anastalsis.
Table 5 Herba Leonuri peace palace capsule is to the influence in mice bleeding time
Annotate: compare * p＜0.05, * * p＜0.01 with matched group
3. Herba Leonuri peace palace capsule is to the influence of animal uterus smooth muscle contraction
3.1 the influence that Herba Leonuri peace palace capsule shrinks at the body uterine smooth muscle rabbit
3.1.1 30 of test method rabbit are divided into 5 groups, are respectively matched group, are subjected to the high, medium and low three dosage groups of reagent, positive drug group, 6 every group.With 10% urethane lumbar injection 5ml/kg, anesthesia back position is fixed on the rabbit platform, the abdominal part cropping is also cut lower abdomen along ventrimeson, expose the uterus, cut an osculum through cornua uteri, the plastic tube that end is had the rubber sacculus inserts intrauterine, slowly inject normal saline from conduit, make the sacculus full of liquid and drain wherein gas, make balloon wall be close to Uterus wall, the other end of conduit links to each other with the TSD140 amplifier by tonotransducer, the variation of record intrauterine pressure, duodenal administration, the record administration before and administration after 30,60,90,120, uterotonic change in 150 minutes (variation of intrauterine pressure).By the MP-100 data acquisition unit, each parameter of continuous record, and be stored in computer, and after waiting to test end, carry out the real-time analysis arrangement with this system-specific program, carry out statistical procedures with the t check.
Table 6-1 Herba Leonuri peace palace capsule is to the influence of rabbit in body uterine smooth muscle contraction intensity
Annotate: compare * p＜0.05, * * p＜0.01 (n=6) with matched group
Table 6-2 Herba Leonuri peace palace capsule is to the influence of rabbit at body uterine smooth muscle contraction frequency
Annotate: compare * p＜0.05, * * p＜0.01 (n=6) with matched group
3.1.2 experimental result table 6 result as seen, Herba Leonuri peace palace capsule institute amount of reagent can be increased in body uterine smooth muscle contraction intensity in various degree, compared significant difference with matched group, high, middle dosage effect is obvious, and uterus smooth muscle contraction frequency is not had obvious influence.
3.2 Herba Leonuri peace palace capsule is to the influence of isolated rat uterine smooth muscle
3.2.1 test method is got female not pregnant rat, test the short feelings of a few days ago subcutaneous 0.1mg/kg injection diethylstilbestrol, put to death rat with the cervical vertebra dislocation method during experiment, cut open the belly and take out the uterus, place the plate that fills Rockwell liquid immediately, softly peel off the connective tissue and the fatty tissue that are attached on the uterus, get the about 2cm of an Aconitum carmichaeli Debx. palace angular length, one end is fixed in the thermostatic bath that contains Rockwell liquid, the other end links to each other with tonotransducer, bath temperature remains on 37 ℃ in the bath, feeds gaseous mixture continuously and (contains 95% O
2With 5% CO
2), per second leads to 1-2 minute bubbles, make the uterus keep the initial tension force of 1g, after treating that the spontaneous contraction in uterus is stable, after writing down one section normal contraction curve, matched group adds 40 μ l nutritional solutions, other groups add the medicinal liquid of equal volume, and the variation of interior intensity of uterine contraction of 20min and frequency after the observation administration is by the MP-100 data acquisition unit, each parameter of continuous record, and be stored in computer, after waiting to test end, carry out real-time analysis with this system-specific program, and the vigor in calculating uterus, vigor=intensity * frequency.
The influence that table 7-1 Herba Leonuri peace palace capsule shrinks normal isolated rat uterine smooth muscle
The influence that table 7-2 Herba Leonuri peace palace capsule shrinks normal isolated rat uterine smooth muscle
The influence that table 7-3 Herba Leonuri peace palace capsule shrinks normal isolated rat uterine smooth muscle
Annotate: compare * p＜0.05, * * p＜0.01 with matched group
3.2.2 result of the test table 7 result as seen, Herba Leonuri peace palace capsule shrinks the isolated rat uterine smooth muscle does not all have obviously influence.
4 antiinflammatory actions
4.1 Herba Leonuri peace palace capsule is to the swollen influence that forms of rat granuloma
[5]
4.1.1 test method is got 50 of SD female rats, body weight 210-240g, lumbar injection 3% pentobarbital sodium 1.0ml/kg anesthesia, every rat abdomen iodine disinfection, after 75% cotton ball soaked in alcohol takes off iodine, cut the long osculum of 1cm, with the autoclaving cotton balls of ophthalmology tweezers with 20mg, it is subcutaneous to implant the both sides groin from incision, immediately skin suture.The postoperative rat is divided into 5 groups immediately by body weight, matched group, aspirin group, the high, medium and low dosage group of Herba Leonuri peace palace capsule.Matched group is pressed 10ml/kg every day and is given distilled water, and all the other each groups are given relative medicine, and continuous 7 days, opened former otch on the 8th day, cotton balls is taken out together with connective tissue on every side, reject fatty tissue, put 37 ℃ in baking oven 24 hours, oven dry is weighed.With claim weight deduct the former weight of cotton balls and promptly get granuloma weight, carry out statistical procedures with the t check.
4.1.2 result of the test table 8 result shows that Herba Leonuri peace palace capsule institute amount of reagent all can obviously suppress the rat granuloma tissue and generate, heavy dose of group of effect is remarkable.
Table 8 Herba Leonuri peace palace capsule is to the swollen influence that forms of rat granuloma
Annotate: compare * p＜0.05, * * p＜0.01 with matched group
4.2. Herba Leonuri peace palace capsule is to the influence of rat uterus inflammation
4.2.1 test method is got 50 of 230-260g SD female rats, lumbar injection 3% pentobarbital sodium 1.0ml/kg anaesthetizes, and cuts belly wool, use iodine disinfection, after 75% cotton ball soaked in alcohol takes off iodine, in abdomen median line otch 2cm, expose the uterus, do at the place transverse incision along 1cm on the cornua uteri of right side, with a plastic tube (caliber 2mm, long 0.5cm, heavy 10mg, alcohol disinfecting) is positioned over intrauterine, with the uterine incision sutured, with slip-off preventing.Wound splashes into penicillin 0.1mg (being dissolved among the water for injection 0.2ml), in case infect skin suture.The postoperative rat is divided into 5 groups, matched group, aspirin group, high, medium and low three the dosage groups of Herba Leonuri peace palace capsule.Matched group is pressed 10ml/kg to distilled water every day, and all the other each groups are given relative medicine, continuous 7 days, kill animals after 7 days is taken out the uterus, both sides, scales/electronic balance weighing, the uterus, right side of every Mus deducts the left side uterus weight, is inflammation swelling degree, carries out statistical procedures with the t check.
4.2.2 result of the test table 9 result shows that Herba Leonuri peace palace capsule can suppress inflammation of uterus rat model intrauterine granulation tissue hyperplasia, has the effect of anti-inflammation of uterus.
The influence that table 9 Herba Leonuri peace palace capsule forms inflammation of uterus rat uterus internal granuloma
Annotate: compare * p＜0.05 with matched group
5 analgesic activities
5.1 the influence of Herba Leonuri peace palace capsule Dichlorodiphenyl Acetate induced mice pain reaction
5.1.1 test method: choose 60 of Healthy female mices, body weight is 19-21g, be divided into 6 groups, every group 10, matched group, high, medium and low three the dosage groups of Herba Leonuri peace palace capsule, positive control drug Herba Leonuri granule group, aspirin group (0.05g/kg) are irritated stomach every day 1 time, and the administration group is pressed the 20ml/kg administration, the blank group is given distilled water, continuous 3d, last administration 1h pneumoretroperitoneum is injected 0.7% glacial acetic acid solution 0.2ml/20g, and the observed and recorded mice is turned round the body number of times after 5 minutes in 15 minutes, difference of each group relatively, and calculate and to turn round the body suppression ratio.
5.1.2 experimental result by table 10 as seen, what Herba Leonuri peace palace capsule institute amount of reagent can reduce all that acetic acid causes mice pain turns round body generation number, and high, middle dosage analgesic activity is obvious, and suppression ratio can reach more than 40%.
5.2 Herba Leonuri peace palace capsule is to the influence of oxytocin induced mice pain reaction
5.2.1 test method is chosen 50 of healthy mature female mices, body weight 19-21g is divided into 5 groups at random, 10 every group, irritate stomach every day 1 time, the blank group gives the distilled water of equal volume, continuous 3d, administration the 1st, 2 two days, subcutaneous injection diethylstilbestrol 0.1ml/10g, 1h lumbar injection oxytocin 0.2u/ only turns round the body number of times in each mice 40min of observed and recorded after the last administration, relatively the difference of each group.
5.2.2 result of the test by table 11 as seen, what Herba Leonuri peace palace capsule institute amount of reagent reduced obviously all that oxytocin causes mice pain turns round body generation number, has compared significant difference with matched group.
6 extracorporeal bacteria inhibitor tests
Test method
Agar dilution.Medicine is added in the agar culture medium that dissolves, make serial doubling dilution, pour into the Agar Plating that becomes to contain different pharmaceutical concentration.With turbidimetry with meat soup increase each bacterial strain of 16 hours of bacterium than turbid to No. 1 the pipe, 300,000,000/1ml, doing suitable dilution by different strains respectively draws 5ul and drips on each concentration pastille flat board, put in 37 ℃ of calorstats and cultivated 24 hours, observe bacterial growth situation in each ware, establish antibacterial contrast, positive control drug contrast simultaneously.
Result of the test table 12 is the result show, cultivates after 24 hours, and antibacterial contrast all has bacterial growth, and Herba Leonuri peace palace capsule all has in various degree inhibitory action to 4 kinds of antibacterial 20 bacterial strains such as the staphylococcus aureus tried.
The outer bacteriostasis (minimum inhibitory concentration) of table 12 Herba Leonuri peace palace capsule body
Annotate: the no bacterial growth of "-" expression, "+" expression has bacterial growth.
By above pharmacological evaluation, show that Herba Leonuri peace palace has following pharmacological action:
1, medicine is caused influencing Herba Leonuri peace palace capsule and can reducing because of medicine and cause the postabortal metrorrhagia of large and small pregnant Mus of pregnant Mus miscarriage, pathological tissue morphological examination result shows, Herba Leonuri peace palace capsule obviously suppresses endometrial thickness, compared significant difference with model control group, high dose group thickens uterine smooth muscle also certain inhibition effect.
2, anastalsis Herba Leonuri peace palace capsule can make the going out of mice, clotting time obviously shorten in institute's amount of reagent scope, has stronger anastalsis.
3, to the influencing Herba Leonuri peace palace capsule and can promote rabbit to shrink at the body uterine smooth muscle of rat uterus smooth muscle, normal isolated rat uterine smooth muscle is shunk does not have obviously influence.
4, antiinflammatory action Herba Leonuri peace palace capsule can suppress the swelling of rat uterus inflammatory model, and the rat granuloma tissue is generated also the obvious suppression effect.
5, analgesic activity Herba Leonuri peace palace capsule is turned round body generation number average to acetic acid and oxytocin induced mice the obvious suppression effect.
6, bacteriostasis Herba Leonuri peace palace capsule all has in various degree inhibitory action to 4 kinds of antibacterial 20 strain clinical isolates such as staphylococcus aureus, escherichia coli, bacillus pyocyaneus, B family streptococcus.
Experimental example 2 clinical experiments
Choosing 50 examples is in May, 2002 to 2002 year JIUYUE, the patient of gynecological of Beijing Hospital of Traditional Chinese Medicine outpatient service prescription on individual diagnosis.By table of random number 50 routine patients are divided into treatment group and matched group, 35 examples are organized in treatment, age 19-43 year, 33.12 ± 5.00 years old mean age; Menolipsis natural law 39-70 days, average 47.28 ± 6.94 days, average pregnant all 6.52 ± 0.57 weeks, average foetal sac diameter 23.96 ± 8.51mm; Matched group 15 examples, age 19-42 year, average 29.33 ± 8.14 years old, menolipsis natural law 38-61 days, average 46.41 ± 5.05 days, average pregnant all 6.41 ± 0.56 weeks, average foetal sac diameter 22.6 ± 6.51mm.Two groups of patients do not have significance (p＞0.05) at aspect comparing differences such as age, pregnant weeks.
Method: medication: equal Rhizoma Atractylodis Macrocephalae day of all cases begins to take medicine, continuous use 7 days.
Treatment group: give Herba Leonuri peace palace capsule, grain number, twice-daily, logotype 7 days.
Matched group: YIMUCAO CHONGJI, 1 bag, twice-daily, logotype 7 days adds simultaneously and uses antibiotic (Levofloxacin Mesylate Tablets) 5 days.
1, observation item and method: after observing two groups of treatments, vaginal hemorrhage natural law, waist abdomen pain situation, heating situation, band are through natural law and menstrual blood volume, and conventional variation before and after the observation treatment.
2, statistical procedures adopts x
2Check with t.
The result: 1, criterion of therapeutical effect is cured in the recent period according to " practical gynecology ": stopped in vaginal hemorrhage 3-5 days, waist stomachache disappears the menstrual cycle rule.Take a turn for the better: vaginal hemorrhage 7-14 days, waist stomachache alleviated, and the cycle is rule still.Invalid: vaginal hemorrhage surpasses 14 days, and waist stomachache is serious, needs to use the antibiotic therapy person.
2, clinical efficacy relatively: 35 examples are organized in treatment, and cure rate 71.43% (25/35) takes a turn for the better 29.57% (10/335) in the recent period; Matched group 15 examples cure 27.27% (4/15) in the recent period, take a turn for the better 72.73% (11/15), and two groups of total effective rates relatively do not have significant difference (p＞0.05), but the cure rate of treatment group and matched group relatively, and difference has significance (x
2=10.46, p＜0.01), illustrate that the merit of its blood stasis dispelling is better than YIMUCAO CHONGJI.
3, two groups of uterine contraction situations and hemorrhage natural law are relatively: treatment is organized hemorrhage natural law and obviously is less than matched group (p＜0.05), illustrates that present composition preparation has good anastalsis.
4, symptoms such as heating, stomachache all do not appear.Illustrate that " Herba Leonuri peace palace capsule " tool has preventive and therapeutic effect to postoperative infection.
Experimental example 3 toxicity tests
1, acute toxicity test: Herba Leonuri peace palace capsule is irritated stomaches three times and is given mice with continuous in the dose of the tolerant Cmax of animal, maximum volume one day, and totally 20, female, maximum dosage-feeding is 531.3g crude drug/kg, is equivalent to 664 times of clinical consumption.At once observe reaction of animals after the administration, and observed continuously 7 days.Death takes place, and the animal body weight average increases, and the overt toxicity reaction is not seen in perusal.
2, long term toxicity test: rat is irritated stomach respectively and gives Herba Leonuri peace palace capsule 40.0,20.0,10.0g crude drug/kg/d, (be equivalent to people's clinical medicine dose 50.0,25.0 and 12.5 times) continuous two months, observes for 2 weeks after the drug withdrawal.Ordinary circumstance, body weight, food-intake to animal during the administration do not have obvious influence, ten biochemical indicators such as peripheral hemogram regulating liver-QI, renal function all fluctuate in normal range, the ponderal index of important organ is not had the obvious macroscopy that influences there is no significant change, also do not see have because the caused obvious pathomorphology of medicine changes through pathological study.
Acute and long term toxicity test shows, present composition preparation application safety.
Following embodiment all can realize the effect of above-mentioned experimental example.
Embodiment 1Capsule
Herba Leonuri 833g Rhizoma Chuanxiong 167g Herba Ecliptae 833g
Herba Leonuri, Herba Ecliptae add 12 times of amounts of water after mixing, and decoct secondary, each 1 hour, filter; Merging filtrate, being concentrated into relative density is 1.15 (50 ℃ of surveys), adds ethanol and makes determining alcohol reach 70%, placement is spent the night, and filters.Rhizoma Chuanxiong adds 5 times of amount 70% alcohol reflux secondaries, each 2 hours, filter, filtrate and above-mentioned alcohol deposit fluid merge, and reclaim ethanol and are concentrated into the thick paste that relative density is 1.28-1.30 (50 ℃ of survey), drying under reduced pressure, be ground into fine powder, the adding lactose is an amount of, mixing, dry-pressing granulates, encapsulated, make 1000 of capsules altogether, promptly.
Embodiment 2Capsule
Herba Leonuri 833g Rhizoma Chuanxiong 167g Herba Ecliptae 833g Herba Houttuyniae 833g
Herba Portulacae 833g, Herba Leonuri, Herba Portulacae, Herba Ecliptae and Herba Houttuyniae add 12 times of amounts of water after mixing, and decoct secondary, each 1 hour, filter; Merging filtrate, being concentrated into relative density is 1.15 (50 ℃ of surveys), adds ethanol and makes determining alcohol reach 70%, placement is spent the night, and filters.Rhizoma Chuanxiong adds 5 times of amount 70% alcohol reflux secondaries, each 2 hours, filter, filtrate and above-mentioned alcohol deposit fluid merge, and reclaim ethanol and are concentrated into the thick paste that relative density is 1. 28-1.30 (50 ℃ of survey), drying under reduced pressure, be ground into fine powder, the adding lactose is an amount of, mixing, dry-pressing granulates, encapsulated, make 1000 of capsules altogether, promptly.
Embodiment 3Capsule
Herba Leonuri 833g Rhizoma Chuanxiong 334g Herba Ecliptae 667g
Herba Houttuyniae 833g Herba Portulacae 833g Rhizoma Cyperi (processed) 500g
[method for making] above Six-element, Rhizoma Cyperi (processed) add 8 times of amounts of water, and steam distillation 6 hours extracts volatile oil, and aqueous solution is continued to employ; Medicinal residues and Herba Leonuri, Herba Portulacae, Herba Ecliptae and Herba Houttuyniae add 12 times of amounts of water after mixing, and decoct secondary, each 1 hour, filter; Merging filtrate and the above-mentioned aqueous solution of carrying behind the oil, being concentrated into relative density is 1.15 (50 ℃ of surveys), adds ethanol and makes determining alcohol reach 70%, placement is spent the night, and filters.Volatile oil betacyclodextrin inclusion (volatile oil-betacyclodextrin-water=1: 8: 80,60 ℃ were stirred 1 hour), cold preservation 24 hours filters cold drying.Rhizoma Chuanxiong adds 5 times of amount 70% alcohol reflux secondaries, each 2 hours, filter, filtrate and above-mentioned alcohol deposit fluid merge, reclaim ethanol and be concentrated into the thick paste that relative density is 1.28-1.30 (50 ℃ of survey), drying under reduced pressure is ground into fine powder and volatile oil betacyclodextrin inclusion complex and mixes, it is an amount of to add lactose, mixing, dry-pressing granulate, encapsulated, make 1000 of capsules altogether, promptly.
Embodiment 4Injection
Herba Leonuri 450g Rhizoma Chuanxiong 190g Herba Ecliptae 360g
Herba Leonuri, Herba Ecliptae and Herba Houttuyniae add 12 times of amounts of water after mixing, and decoct secondary, each 1 hour, filter; Merging filtrate, being concentrated into relative density is 1.15 (50 ℃ of surveys), adds ethanol and makes determining alcohol reach 70%, placement is spent the night, and filters.Rhizoma Chuanxiong adds 5 times of amount 70% alcohol reflux secondaries, each 2 hours, filters, filtrate and above-mentioned alcohol deposit fluid merge, and reclaim ethanol and are concentrated into the extractum that relative density is 1.1-1.15 (50 ℃ of survey), add ethanol and make determining alcohol reach 80%, ethanol is reclaimed in cold preservation 48 hours, is concentrated into about 500ml, add water for injection and proper auxiliary materials, be made into 1000ml, after filtration, pour into the 10ml ampoule, sterilization, promptly.
Embodiment 5Granule
Herba Leonuri 1083g Rhizoma Chuanxiong 333g Herba Ecliptae 1250g
Herba Houttuyniae 1250g Herba Portulacae 1250g
Herba Leonuri, Herba Portulacae, Herba Ecliptae and Herba Houttuyniae add 12 times of amounts of water after mixing, and decoct secondary, each 1 hour, filter; Merging filtrate, being concentrated into relative density is 1.15 (50 ℃ of surveys), adds ethanol and makes determining alcohol reach 70%, placement is spent the night, and filters.Rhizoma Chuanxiong adds 5 times of amount 70% alcohol reflux secondaries, and each 2 hours, filter, filtrate and above-mentioned alcohol deposit fluid merge, and reclaim ethanol and are concentrated into the thick paste that relative density is 1.28-1.30 (50 ℃ of survey), and drying under reduced pressure is ground into fine powder, and often regulation becomes granule.
Embodiment 6Tablet
Herba Leonuri 1083g Rhizoma Chuanxiong 333g Herba Ecliptae 1250g
Herba Houttuyniae 1250g Herba Portulacae 1250g Rhizoma Cyperi (processed) 666g,
[method for making] above Six-element, Rhizoma Cyperi (processed) add 8 times of amounts of water, and steam distillation 8 hours extracts volatile oil, and aqueous solution is continued to employ; Medicinal residues and Herba Leonuri, Herba Portulacae, Herba Ecliptae and Herba Houttuyniae add 12 times of amounts of water after mixing, and decoct secondary, each 1 hour, filter; Merging filtrate and the above-mentioned aqueous solution of carrying behind the oil, being concentrated into relative density is 1.15 (50 ℃ of surveys), adds ethanol and makes determining alcohol reach 70%, placement is spent the night, and filters.Volatile oil betacyclodextrin inclusion (volatile oil-betacyclodextrin-water=1: 8: 100,60 ℃ were stirred 1 hour), cold preservation 24 hours filters cold drying.Rhizoma Chuanxiong adds 5 times of amount 70% alcohol reflux secondaries, each 2 hours, filter, filtrate and above-mentioned alcohol deposit fluid merge, and reclaim ethanol and are concentrated into the thick paste that relative density is 1.28-1.30 (50 ℃ of survey), drying under reduced pressure, be ground into fine powder and volatile oil betacyclodextrin inclusion complex and mix, adding starch is an amount of, mixing, often regulation becomes tablet.
Embodiment 7Injection
Herba Leonuri 666g Rhizoma Chuanxiong 250g Herba Ecliptae 666g,
Herba Leonuri, Herba Ecliptae add 12 times of amounts of water after mixing, and decoct secondary, each 1 hour, filter; Merging filtrate, being concentrated into relative density is 1.15 (50 ℃ of surveys), adds ethanol and makes determining alcohol reach 70%, placement is spent the night, and filters.Rhizoma Chuanxiong adds 5 times of amount 70% alcohol reflux secondaries, each 2 hours, filters, filtrate and above-mentioned alcohol deposit fluid merge, and reclaim ethanol and are concentrated into the extractum that relative density is 1.1-1.15 (50 ℃ of survey), add ethanol and make determining alcohol reach 80%, ethanol is reclaimed in cold preservation 48 hours, is concentrated into about 500ml, add water for injection and proper auxiliary materials, be made into 1000ml, after filtration, pour into the 10ml ampoule, sterilization, promptly.
Embodiment 8Oral liquid
Herba Leonuri 666g Rhizoma Chuanxiong 250g Herba Ecliptae 666g
Herba Houttuyniae 833g Herba Portulacae 666g
Herba Leonuri, Herba Portulacae, Herba Ecliptae and Herba Houttuyniae add 12 times of amounts of water after mixing, and decoct secondary, each 1 hour, filter; Merging filtrate, being concentrated into relative density is 1.15 (50 ℃ of surveys), adds ethanol and makes determining alcohol reach 70%, placement is spent the night, and filters.Rhizoma Chuanxiong adds 5 times of amount 70% alcohol reflux secondaries, each 2 hours, filter, filtrate and above-mentioned alcohol deposit fluid merge, and reclaim ethanol and are concentrated into the extractum that relative density is 1.15-1.20 (50 ℃ of survey), add an amount of syrup, purified water and an amount of other adjuvants, make 3000ml, pour into the 10ml bottle, promptly.Each one, every day three times.
Embodiment 9Tablet
Herba Leonuri 666g Rhizoma Chuanxiong 334g Herba Ecliptae 667g
Herba Houttuyniae 833g Herba Portulacae 666g Rhizoma Cyperi (processed) 417g
[method for making] above Six-element, Rhizoma Cyperi (processed) add 8 times of amounts of water, and steam distillation 8 hours extracts volatile oil, and aqueous solution is continued to employ; Medicinal residues and Herba Leonuri, Herba Portulacae, Herba Ecliptae and Herba Houttuyniae add 12 times of amounts of water after mixing, and decoct secondary, each 1 hour, filter; Merging filtrate and the above-mentioned aqueous solution of carrying behind the oil, being concentrated into relative density is 1.15 (50 ℃ of surveys), adds ethanol and makes determining alcohol reach 70%, placement is spent the night, and filters.Volatile oil betacyclodextrin inclusion (volatile oil-betacyclodextrin-water=1: 8: 100,60 ℃ were stirred 1 hour), cold preservation 24 hours filters cold drying.Rhizoma Chuanxiong adds 5 times of amount 70% alcohol reflux secondaries, each 2 hours, filter, filtrate and above-mentioned alcohol deposit fluid merge, and reclaim ethanol and are concentrated into the thick paste that relative density is 1.28-1.30 (50 ℃ of survey), drying under reduced pressure, be ground into fine powder and volatile oil betacyclodextrin inclusion complex and mix, adding starch is an amount of, mixing, often regulation becomes tablet.
Claims (13)
1. a treatment, prevention puerperal and postoperative complication of artificial abortion's Chinese medicine composition is characterized in that this Chinese medicine composition made by following raw material medicaments:
Herba Leonuri 5-20 weight portion Rhizoma Chuanxiong 1-10 weight portion Herba Ecliptae 5-20 weight portion.
2. Chinese medicine composition as claimed in claim 1 is characterized in that this Chinese medicine composition made by following raw material medicaments:
Herba Leonuri 7-15 weight portion Rhizoma Chuanxiong 1-6 weight portion Herba Ecliptae 7-15 weight portion.
3. Chinese medicine composition as claimed in claim 2 is characterized in that this Chinese medicine composition made by following raw material medicaments:
Herba Leonuri 10 weight portion Rhizoma Chuanxiongs 2 weight portion Herba Ecliptaes 10 weight portions.
4. a treatment, prevention puerperal and postoperative complication of artificial abortion's Chinese medicine composition is characterized in that this Chinese medicine composition made by following raw material medicaments:
Herba Leonuri 5-20 weight portion Rhizoma Chuanxiong 1-10 weight portion Herba Houttuyniae 5-20 weight portion
Herba Ecliptae 5-20 weight portion Herba Portulacae 5-20 weight portion.
5. Chinese medicine composition as claimed in claim 4 is characterized in that this Chinese medicine composition made by following raw material medicaments:
Herba Leonuri 7-15 weight portion Rhizoma Chuanxiong-16 weight portion Herba Houttuyniae 7-15 weight portion
Herba Ecliptae 7-15 weight portion Herba Portulacae 7-15 weight portion.
6. Chinese medicine composition as claimed in claim 5 is characterized in that this Chinese medicine composition mainly made by following raw material medicaments:
Herba Leonuri 10 weight portion Rhizoma Chuanxiongs 2 weight portion Herba Ecliptaes 10 weight portions
Herba Houttuyniae 10 weight portion Herba Portulacaes 10 weight portions.
7. a treatment, prevention puerperal and postoperative complication of artificial abortion's Chinese medicine composition is characterized in that this Chinese medicine composition made by following raw material medicaments:
Herba Leonuri 5-20 weight portion Rhizoma Chuanxiong 1-10 weight portion Herba Houttuyniae 5-20 weight portion
Rhizoma Cyperi 3-12 weight portion lotus grass 5-20 weight portion Herba Portulacae 5-20 weight portion.
8. Chinese medicine composition as claimed in claim 7 is characterized in that this Chinese medicine composition made by following raw material medicaments:
Herba Leonuri 7-15 weight portion Rhizoma Chuanxiong 1-6 weight portion Herba Houttuyniae 7-15 weight portion
Rhizoma Cyperi 5-9 weight portion Herba Ecliptae 7-15 weight portion Herba Portulacae 7-15 weight portion.
9. Chinese medicine composition as claimed in claim 8 is characterized in that this Chinese medicine composition made by following raw material medicaments:
Herba Leonuri 10 weight portion Rhizoma Chuanxiongs 2 weight portion Herba Ecliptaes 10 weight portions
Herba Houttuyniae 8 weight portion Herba Portulacaes 9 weight portion Rhizoma Cyperi (processed) 7 weight portions.
10. as the arbitrary described Chinese medicine composition of claim 7-9, it is characterized in that Rhizoma Cyperi is selected Rhizoma Cyperi (processed) for use in this traditional Chinese medicinal composition raw materials.
11. the preparation method of Chinese medicine composition as claimed in claim 10 is characterized in that this method is: Rhizoma Cyperi (processed) adds water 6-10 doubly to be measured, and steam distillation 6-10 hour, extract volatile oil, aqueous solution is continued to employ; Add water 10-15 after medicinal residues and Herba Leonuri, Herba Portulacae, Herba Ecliptae and Herba Houttuyniae mix and doubly measure, decoct 1-3 time, each 1-2 hour, filter; Merging filtrate and the above-mentioned aqueous solution of carrying behind the oil, being concentrated into 45-60 ℃, to survey relative density be 1.10-1.20, adds ethanol and make determining alcohol reach 60-80%, placement is spent the night, and filters; Volatile oil betacyclodextrin inclusion cold preservation 20-28 hour, filters cold drying; Rhizoma Chuanxiong adds 4-6 and doubly measures the 60-80% alcohol reflux 1-3 time, each 1-3 hour, filter, filtrate and above-mentioned alcohol deposit fluid merge, reclaim ethanol and be concentrated into the thick paste that relative density is 1.28-1.30 45-60 ℃ of survey, drying under reduced pressure is ground into fine powder, mix with volatile oil betacyclodextrin inclusion complex, directly or indirectly add excipient film-making agent, oral liquid, capsule, granule, injection, freeze-dried powder or the slow releasing preparation of pharmaceutically accepting through conventional operation.
12. the preparation method of Chinese medicinal composition capsules agent as claimed in claim 11 is characterized in that this method is: Rhizoma Cyperi (processed) adds 8 times of amounts of water, steam distillation 8 hours extracts volatile oil, and aqueous solution is continued to employ; Medicinal residues and Herba Leonuri, Herba Portulacae, Herba Ecliptae and Herba Houttuyniae add 12 times of amounts of water after mixing, and decoct secondary, each 1 hour, filter; Merging filtrate and the above-mentioned aqueous solution of carrying behind the oil, being concentrated into 50 ℃, to survey relative densities be 1.15, adds ethanol and make determining alcohol reach 70%, placement is spent the night, and filters; Volatile oil betacyclodextrin inclusion, cold preservation 24 hours filters cold drying; Rhizoma Chuanxiong adds 5 times of amount 70% alcohol reflux secondaries, each 2 hours, filter, filtrate and above-mentioned alcohol deposit fluid merge, reclaiming ethanol and being concentrated into 50 ℃ of survey relative densities is the thick paste of 1.28-1.30, drying under reduced pressure is ground into fine powder and volatile oil betacyclodextrin inclusion complex and mixes, it is an amount of to add starch, mixing, dry-pressing granulation, encapsulated, promptly.
13. as the preparation method of claim 11 or 12 described Chinese medicine compositions, it is characterized in that volatile oil described in this method is volatile oil-betacyclodextrin-water=1: 8: 80 with betacyclodextrin inclusion method, 60 ℃ were stirred 1 hour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101022832A CN100418559C (en) | 2003-10-30 | 2003-10-30 | Chinese medicinal composition for treating postartum and abortive complication and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101022832A CN100418559C (en) | 2003-10-30 | 2003-10-30 | Chinese medicinal composition for treating postartum and abortive complication and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1611230A CN1611230A (en) | 2005-05-04 |
| CN100418559C true CN100418559C (en) | 2008-09-17 |
Family
ID=34756353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101022832A Expired - Lifetime CN100418559C (en) | 2003-10-30 | 2003-10-30 | Chinese medicinal composition for treating postartum and abortive complication and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100418559C (en) |
-
2003
- 2003-10-30 CN CNB2003101022832A patent/CN100418559C/en not_active Expired - Lifetime
Non-Patent Citations (4)
| Title |
|---|
| 益母复原汤治疗产后子宫复旧不良38例. 王心好等.实用中西医结合杂志，第4卷第4期. 1991 |
| 益母复原汤治疗产后子宫复旧不良38例. 王心好等.实用中西医结合杂志，第4卷第4期. 1991 * |
| 逐淤汤治疗早期人工流产术后阴道出血29例. 段世彪.湖北中医杂志，第6期. 1986 |
| 逐淤汤治疗早期人工流产术后阴道出血29例. 段世彪.湖北中医杂志，第6期. 1986 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1611230A (en) | 2005-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101380440A (en) | Use of Yunkang oral liquid in preparing medicine for treating kidney-deficiency type sterility | |
| CN101069726B (en) | Chinese medicine preparation of expelling toxin by cooling and eliminating damp and removing stasis, preparing method and use | |
| CN104721418B (en) | It is a kind of to be used to treat pharmaceutical composition of gynaecological imflammation and preparation method thereof and purposes | |
| CN109045162B (en) | Traditional Chinese medicine composition for treating endometriosis and application thereof | |
| CN100394919C (en) | Medicinal composition for treating vagina disease | |
| CN100418559C (en) | Chinese medicinal composition for treating postartum and abortive complication and its preparing method | |
| CN102526620B (en) | Traditional Chinese medicinal composition for treating gynecological inflammation and application of same | |
| CN105267472A (en) | Traditional Chinese medicine medicament for treating gynecological diseases and applications thereof | |
| CN1320451A (en) | Exterior-applied medicine for treating gynopathy | |
| CN102755563A (en) | Chinese medicinal composition for treating chronic prostatitis and preparation method thereof | |
| CN101366878A (en) | Traditional Chinese medicine for female acyesis and aphoria and preparation method thereof | |
| CN101322771A (en) | Capsules for treating gynecology inflammation | |
| CN101019981A (en) | Chinese medicine prepn and its preparing process | |
| CN100369624C (en) | Chinese medicinal composition for treating chronic pelvic inflammation and its preparation method | |
| CN108686018A (en) | A kind of kuh-seng Cortex Phellodendri inhibiting-bacteria preparation and preparation method thereof | |
| CN115025108B (en) | A pharmaceutical composition for treating pelvic inflammatory disease and preparation method thereof | |
| CN114377063B (en) | Traditional Chinese medicine composition for treating delayed fracture healing | |
| CN101601832A (en) | A kind of medicine for the treatment of chronic pelvic inflammatory disease and preparation method thereof | |
| CN103372063B (en) | Traditional Chinese medicine composition for treating sequelae of pelvic inflammatory disease and use thereof | |
| CN104225034B (en) | Application of composition in preparing medicine for treating non-infectious urethral syndrome | |
| CN101455809A (en) | Traditional Chinese medicine composition for treating hyperplasia of mammary glands and preparation method thereof | |
| CN117815296A (en) | A Chinese medicinal composition for treating gynecological diseases, and its preparation method and application | |
| CN100443093C (en) | AIDS treating medicine | |
| CN104815310A (en) | Medicine for removing embryonic tissue residues | |
| CN105560668A (en) | Pharmaceutical composition for curing immune infertility |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 044600 Fumin Road, Ruicheng, Shanxi, No. 43 Patentee after: SHANXI YABAO PHARMACEUTICAL Group Corp. Address before: 044600 Fumin Road, Ruicheng, Shanxi, No. 43 Patentee before: Shanxi Yabao Pharmaceutical Group Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20080917 |
|
| CX01 | Expiry of patent term |